CD44 and ovarian cancer: While the molecular target of Cantrixil is yet to be confirmed, it has been identified as having potent cytotoxicity against chemoresistant CD44+/MyD88+ ovarian CSC clones and chemosensitive CD44-/MyD88- ovarian cancer cell lines [28].